August 25, 2021 "We are currently developing 1) LFTs (lateral flow test kits) for TBI (traumatic brain injury, aka concussions), 2) a multiplex test that detects Covid-19, Flu and RSV (Respiratory Syncytial Virus), and 3) a vaccine validator (vac-check done) to thwart counterfeit vaccines and validate vaccine efficacy."
"In addition, the Company has signed a term sheet with a Canada-based biotech company that has identified (Neurolytixs announced partnership) and has a patent-pending on several biomarker candidates that will be used to develop the TBI POCT. The term sheet is non-binding and we can provide no assurance that we will be able to reach definitive agreements on terms acceptable to the Company. We are in the process of negotiating the final terms that include the payment milestones required for QMC to design, develop, shepherd the FDA approval process, and produce the test kits."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.